Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells

Tomohiro Shibata, Hitoshi Kan, Yuichi Murakami, Hiroki Ureshino, Kosuke Watari, Akihiko Kawahara, Masayoshi Kage, Satoshi Hattori, Mayumi Ono, Michihiko Kuwano

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Gene amplification of HER2/ErbB2 occurs in gastric cancer and the therapeutic efficacy of the HER2-targeted antibody, trastuzumab, has recently been improved against HER2-positive advanced stomach cancer. Here, we examined whether Y-box-binding protein-1 (YB-1) could selectively control HER2 gene expression and cellular sensitivity to EGF receptor (EGFR) family protein-targeted drugs in human gastric cancer cells. HER2 expression was specifically downregulated by YB-1 silencing using its cognate siRNA, whereas there was less change in the expression of EGFRand HER3. Achromatin immunoprecipitation assay revealed the specific binding of YB-1 to its consensus sequence on the 5′-regulatory region of HER2. YB-1 knockdown induced drug resistance to lapatinib, a dual EGFR and HER2 kinase inhibitor, and also to erlotinib, an EGFR kinase inhibitor. Moreover, phosphorylation of protein kinase B (Akt) was not markedly affected by lapatinib or erlotinib when YB-1 was silenced. Nuclear YB-1 expression was significantly (P = 0.026) associated with HER2 expression, but not with EGFR or HER3, in patients with gastric cancer (n = 111). The YB-1-HER2 axis may therefore be useful for the further development of personalized therapeutics against gastric cancer by HER2-targeted drugs.

Original languageEnglish
Pages (from-to)737-746
Number of pages10
JournalMolecular Cancer Therapeutics
Volume12
Issue number5
DOIs
Publication statusPublished - May 1 2013
Externally publishedYes

Fingerprint

Y-Box-Binding Protein 1
Stomach Neoplasms
Epidermal Growth Factor Receptor
Phosphotransferases
erbB-2 Genes
Proto-Oncogene Proteins c-akt
Gene Amplification
Nucleic Acid Regulatory Sequences
Consensus Sequence
Immunoprecipitation
Drug Resistance
Pharmaceutical Preparations
Small Interfering RNA
Down-Regulation
Phosphorylation
lapatinib
Gene Expression
Antibodies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. / Shibata, Tomohiro; Kan, Hitoshi; Murakami, Yuichi; Ureshino, Hiroki; Watari, Kosuke; Kawahara, Akihiko; Kage, Masayoshi; Hattori, Satoshi; Ono, Mayumi; Kuwano, Michihiko.

In: Molecular Cancer Therapeutics, Vol. 12, No. 5, 01.05.2013, p. 737-746.

Research output: Contribution to journalArticle

Shibata, T, Kan, H, Murakami, Y, Ureshino, H, Watari, K, Kawahara, A, Kage, M, Hattori, S, Ono, M & Kuwano, M 2013, 'Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells', Molecular Cancer Therapeutics, vol. 12, no. 5, pp. 737-746. https://doi.org/10.1158/1535-7163.MCT-12-1125
Shibata, Tomohiro ; Kan, Hitoshi ; Murakami, Yuichi ; Ureshino, Hiroki ; Watari, Kosuke ; Kawahara, Akihiko ; Kage, Masayoshi ; Hattori, Satoshi ; Ono, Mayumi ; Kuwano, Michihiko. / Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. In: Molecular Cancer Therapeutics. 2013 ; Vol. 12, No. 5. pp. 737-746.
@article{82c24994fbf746529b343d12e195d559,
title = "Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells",
abstract = "Gene amplification of HER2/ErbB2 occurs in gastric cancer and the therapeutic efficacy of the HER2-targeted antibody, trastuzumab, has recently been improved against HER2-positive advanced stomach cancer. Here, we examined whether Y-box-binding protein-1 (YB-1) could selectively control HER2 gene expression and cellular sensitivity to EGF receptor (EGFR) family protein-targeted drugs in human gastric cancer cells. HER2 expression was specifically downregulated by YB-1 silencing using its cognate siRNA, whereas there was less change in the expression of EGFRand HER3. Achromatin immunoprecipitation assay revealed the specific binding of YB-1 to its consensus sequence on the 5′-regulatory region of HER2. YB-1 knockdown induced drug resistance to lapatinib, a dual EGFR and HER2 kinase inhibitor, and also to erlotinib, an EGFR kinase inhibitor. Moreover, phosphorylation of protein kinase B (Akt) was not markedly affected by lapatinib or erlotinib when YB-1 was silenced. Nuclear YB-1 expression was significantly (P = 0.026) associated with HER2 expression, but not with EGFR or HER3, in patients with gastric cancer (n = 111). The YB-1-HER2 axis may therefore be useful for the further development of personalized therapeutics against gastric cancer by HER2-targeted drugs.",
author = "Tomohiro Shibata and Hitoshi Kan and Yuichi Murakami and Hiroki Ureshino and Kosuke Watari and Akihiko Kawahara and Masayoshi Kage and Satoshi Hattori and Mayumi Ono and Michihiko Kuwano",
year = "2013",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-12-1125",
language = "English",
volume = "12",
pages = "737--746",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells

AU - Shibata, Tomohiro

AU - Kan, Hitoshi

AU - Murakami, Yuichi

AU - Ureshino, Hiroki

AU - Watari, Kosuke

AU - Kawahara, Akihiko

AU - Kage, Masayoshi

AU - Hattori, Satoshi

AU - Ono, Mayumi

AU - Kuwano, Michihiko

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Gene amplification of HER2/ErbB2 occurs in gastric cancer and the therapeutic efficacy of the HER2-targeted antibody, trastuzumab, has recently been improved against HER2-positive advanced stomach cancer. Here, we examined whether Y-box-binding protein-1 (YB-1) could selectively control HER2 gene expression and cellular sensitivity to EGF receptor (EGFR) family protein-targeted drugs in human gastric cancer cells. HER2 expression was specifically downregulated by YB-1 silencing using its cognate siRNA, whereas there was less change in the expression of EGFRand HER3. Achromatin immunoprecipitation assay revealed the specific binding of YB-1 to its consensus sequence on the 5′-regulatory region of HER2. YB-1 knockdown induced drug resistance to lapatinib, a dual EGFR and HER2 kinase inhibitor, and also to erlotinib, an EGFR kinase inhibitor. Moreover, phosphorylation of protein kinase B (Akt) was not markedly affected by lapatinib or erlotinib when YB-1 was silenced. Nuclear YB-1 expression was significantly (P = 0.026) associated with HER2 expression, but not with EGFR or HER3, in patients with gastric cancer (n = 111). The YB-1-HER2 axis may therefore be useful for the further development of personalized therapeutics against gastric cancer by HER2-targeted drugs.

AB - Gene amplification of HER2/ErbB2 occurs in gastric cancer and the therapeutic efficacy of the HER2-targeted antibody, trastuzumab, has recently been improved against HER2-positive advanced stomach cancer. Here, we examined whether Y-box-binding protein-1 (YB-1) could selectively control HER2 gene expression and cellular sensitivity to EGF receptor (EGFR) family protein-targeted drugs in human gastric cancer cells. HER2 expression was specifically downregulated by YB-1 silencing using its cognate siRNA, whereas there was less change in the expression of EGFRand HER3. Achromatin immunoprecipitation assay revealed the specific binding of YB-1 to its consensus sequence on the 5′-regulatory region of HER2. YB-1 knockdown induced drug resistance to lapatinib, a dual EGFR and HER2 kinase inhibitor, and also to erlotinib, an EGFR kinase inhibitor. Moreover, phosphorylation of protein kinase B (Akt) was not markedly affected by lapatinib or erlotinib when YB-1 was silenced. Nuclear YB-1 expression was significantly (P = 0.026) associated with HER2 expression, but not with EGFR or HER3, in patients with gastric cancer (n = 111). The YB-1-HER2 axis may therefore be useful for the further development of personalized therapeutics against gastric cancer by HER2-targeted drugs.

UR - http://www.scopus.com/inward/record.url?scp=84877646454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877646454&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-12-1125

DO - 10.1158/1535-7163.MCT-12-1125

M3 - Article

VL - 12

SP - 737

EP - 746

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -